Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 4
2014 6
2015 2
2016 12
2017 13
2018 14
2019 5
2020 3
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Among authors: somaratne r. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Free article. Clinical Trial.
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Nicholls SJ, et al. Among authors: somaratne r. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. JAMA. 2016. PMID: 27846344 Clinical Trial.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Sabatine MS, et al. Among authors: somaratne r. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Free article. Clinical Trial.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Bonaca MP, et al. Among authors: somaratne r. Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133605 Free article. Clinical Trial.
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
Nicholls SJ, Nissen SE, Prati F, Windecker S, Kataoka Y, Puri R, Hucko T, Kassahun H, Liao J, Somaratne R, Butters J, Di Giovanni G, Jones S, Psaltis PJ. Nicholls SJ, et al. Among authors: somaratne r. Cardiovasc Diagn Ther. 2021 Feb;11(1):120-129. doi: 10.21037/cdt-20-684. Cardiovasc Diagn Ther. 2021. PMID: 33708484 Free PMC article.
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Nissen SE, et al. Among authors: somaratne r. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608. JAMA. 2016. PMID: 27039291 Clinical Trial.
Evolocumab: Considerations for the Management of Hyperlipidemia.
Wiggins BS, Senfield J, Kassahun H, Lira A, Somaratne R. Wiggins BS, et al. Among authors: somaratne r. Curr Atheroscler Rep. 2018 Mar 6;20(4):17. doi: 10.1007/s11883-018-0720-3. Curr Atheroscler Rep. 2018. PMID: 29511875 Review.
Effect of Evolocumab on Lipoprotein Particles.
Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Toth PP, et al. Among authors: somaratne r. Am J Cardiol. 2018 Feb 1;121(3):308-314. doi: 10.1016/j.amjcard.2017.10.028. Epub 2017 Nov 8. Am J Cardiol. 2018. PMID: 29221604 Clinical Trial.
Thiol adsorption on metal oxide nanoparticles.
Grimm OC , Somaratne RMDS , Wang Y , Kim S , Whitten JE . Grimm OC , et al. Among authors: somaratne rmds. Phys Chem Chem Phys. 2021 Apr 14;23(14):8309-8317. doi: 10.1039/d1cp00506e. Epub 2021 Mar 26. Phys Chem Chem Phys. 2021. PMID: 33875995
58 results